Please login to the form below

Not currently logged in

ProStraken gets German approval for cancer pain drug

Speciality pharmaceutical company ProStraken Group has received a marketing authorisation for Abstral

Speciality pharmaceutical company ProStraken Group has received a marketing authorisation for Abstral, its cancer pain drug, from the German Federal Institute for Drugs and Medical Devices (BfArM).

The company plans to launch Abstral, which was formerly branded as Rapinyl, in Germany and the UK at the beginning of 2009, and wider across Europe throughout the year.

Abstral is a fast-dissolving tablet for sub-lingual administration of fentanyl and is intended for the treatment of cancer pain in patients already receiving opioid analgesics.

Dr Wilson Totten, chief executive of ProStrakan, said: "Germany is an important market for Abstral and its approval by BfArM is a significant step forward towards its launch there. Our German operation is well advanced in its preparations for launch and we look forward to introducing German oncologists to this important product for cancer patients suffering from the debilitating effects of breakthrough pain."

ProStraken has in-licensed the exclusive rights to Abstral in Europe and North America from Orexo AB, a Swedish pharmaceutical company. The companies jointly launched the drug in Sweden in August 2008.

15th December 2008


Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....